What is Synthace?
Headquartered in London and Boston, Synthace is redefining the biological discovery process through its proprietary cloud-based platform, Antha. The software serves as a sophisticated interface that allows biologists to program lab automation without the requirement for complex coding. By bridging the gap between experimental design and automated execution, Synthace enables researchers to optimize workflows, enhance data reproducibility, and accelerate the pace of innovation in biotechnology. The platform is specifically engineered to handle the intricacies of modern biological research, providing a seamless transition from planning to data analysis.
How much funding has Synthace raised?
Synthace has raised a total of $72.1M across 4 funding rounds:
Angel/Seed
$2.1M
Series A
$9.4M
Series B
$25.6M
Series C
$35M
Angel/Seed (2013): $2.1M with participation from Sofinnova Partners
Series A (2017): $9.4M led by Sofinnova Partners, Amadeus Capital Partners, White Cloud Capital, Bioeconomy Capital., SOSV, and 11.2 Capital
Series B (2018): $25.6M supported by Horizons Ventures
Series C (2021): $35M featuring Horizons Ventures and Sofinnova Partners
Key Investors in Synthace
Sofinnova Partners
A leading European venture capital firm in life sciences, specializing in healthcare and sustainability with a focus on company building from seed to later-stage.
Horizons Ventures
A venture firm focused on deep science and technology, dedicated to supporting transformative projects that advance humanity.
Amadeus Capital Partners
A London-based global technology venture capital firm investing in high-growth sectors including digital health, enterprise software, and deep tech.
What's next for Synthace?
With the infusion of $35M, Synthace is well-positioned to scale its enterprise-level operations and expand the reach of its Antha platform. The company's strategic roadmap focuses on deepening its integration with existing laboratory hardware and broadening its user base across global pharmaceutical and academic sectors. As the industry shifts toward high-throughput, data-driven experimentation, Synthace is poised to capture significant market share by providing the essential software layer that powers the next generation of biological discovery and synthetic biology advancements.
See full Synthace company page
